^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD1 inhibitor

    Related drugs:
    Apply
    Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients (NeoCARD) (NCT06845319)
    Phase 2
    Medical University of South Carolina
    Not yet recruiting
    Last update posted :
    02/25/2025
    Initiation :
    06/01/2025
    Primary completion :
    06/30/2027
    Completion :
    06/30/2028
    BRCA
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (NCT02339571)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/23/2015
    Primary completion :
    06/30/2033
    Completion :
    06/30/2033
    BRAF
    |
    BRAF mutation • BRAF wild-type
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Leukine (sargramostim)
    Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations (SWOG S2001) (NCT04548752)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/22/2021
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    BRCA1 • BRCA
    |
    BRCA mutation
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin • Pembroria (pembrolizumab biosimilar)
    Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy (NCT04963153)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/07/2022
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    PD-L1 • FGFR2 • NECTIN4
    |
    PD-L1 expression
    |
    Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
    TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05507541)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/19/2023
    Primary completion :
    11/01/2026
    Completion :
    11/01/2027
    PD-L1 • ALK • BCL2 • BCL6 • IRF4
    |
    ALK positive
    |
    Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)
    Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) (NCT06041503)
    Phase 2
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/27/2025
    Primary completion :
    10/01/2027
    Completion :
    10/01/2028
    CD4
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer. (ACCESS-I) (NCT06670911)
    Phase 2
    Instituto Nacional de Cancer, Brazil
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/20/2025
    Primary completion :
    04/01/2026
    Completion :
    04/01/2028
    PD-L1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel
    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (NCT05111574)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    08/11/2022
    Primary completion :
    12/19/2025
    Completion :
    12/19/2025
    PD-L1
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma (NCT05083754)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    08/31/2022
    Primary completion :
    01/01/2026
    Completion :
    01/01/2027
    PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS
    |
    temozolomide • carmustine • Zynyz (retifanlimab-dlwr)
    Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery (SWOG 1512) (NCT02775851)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/06/2017
    Primary completion :
    04/14/2023
    Completion :
    05/15/2026
    TMB • CD8 • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (AdvanTIG-206) (NCT04948697)
    Phase 2
    BeiGene
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    08/20/2021
    Primary completion :
    02/01/2024
    Completion :
    02/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma (NCT03138161)
    Phase 1/2
    Sarcoma Oncology Research Center, LLC
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/13/2017
    Primary completion :
    12/31/2030
    Completion :
    07/31/2031
    PD-L1 • PD-1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Yondelis (trabectedin)
    Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (NCT04243616)
    Phase 2
    Medical College of Wisconsin
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/05/2020
    Primary completion :
    07/14/2025
    Completion :
    08/13/2025
    HER-2 • PD-L1 • PGR • PD-L2
    |
    PD-L1 expression • HER-2 negative • PGR positive
    |
    carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal
    ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) (NCT05671510)
    Phase 3
    OncoC4, Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/28/2023
    Primary completion :
    06/30/2026
    Completion :
    06/30/2027
    LAG3 • CTLA4 • TIGIT
    |
    docetaxel • gotistobart (BNT316)
    Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia (NCT04712851)
    Phase 2
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/30/2021
    Primary completion :
    01/31/2026
    Completion :
    01/31/2027
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004) (NCT06345729)
    Phase 3
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/24/2024
    Primary completion :
    02/19/2029
    Completion :
    02/18/2031
    KRAS
    |
    Keytruda (pembrolizumab) • MK-1084
    Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NRG-GY003) (NCT02498600)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/29/2015
    Primary completion :
    09/05/2018
    Completion :
    12/31/2025
    PD-L1
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar)
    Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (NCI#10057) (NCT02978625)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/27/2017
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    PD-L1 • ALK • NECTIN1
    |
    ALK positive • ALK negative
    |
    Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors (NCT04669496)
    Phase 2/3
    Shanghai Zhongshan Hospital
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    01/20/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    TMB • MSI • CEACAM5 • MUC16
    |
    PD-L1 expression
    |
    Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin
    Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer (AIM-NIVO) (NCT03816345)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    07/16/2019
    Primary completion :
    08/31/2026
    Completion :
    08/31/2026
    MSI • IL2
    |
    Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) (NCT03829319)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    02/21/2025
    Initiation :
    03/25/2019
    Primary completion :
    08/11/2023
    Completion :
    08/30/2024
    EGFR • ALK • ROS1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Lenvima (lenvatinib) • pemetrexed
    Reinvigorating TNBC Response to Immunotherapy with Combination Myeloid Inhibition and Radiation (NCT05491226)
    Phase 2
    Stephen Shiao
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/17/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    HER-2 • PD-L1
    |
    Keytruda (pembrolizumab) • Niktimvo (axatilimab-csfr)
    A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (ARTEMIDE-Lung03) (NCT06627647)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/27/2024
    Primary completion :
    05/10/2029
    Completion :
    03/25/2030
    PD-L1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • rilvegostomig (AZD2936)
    Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (REMAIN) (NCT06029270)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    07/15/2024
    Primary completion :
    04/30/2029
    Completion :
    04/30/2029
    PD-L1 • LAG3
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar)
    Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer (NCT04990921)
    Phase 2
    University of Louisville
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    09/02/2021
    Primary completion :
    07/01/2031
    Completion :
    07/01/2031
    HER-2 • ER
    |
    HER-2 overexpression
    |
    Keytruda (pembrolizumab)
    Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D) (MK-3475-016) (NCT04098068)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Completed
    Last update posted :
    02/20/2025
    Initiation :
    01/25/2018
    Primary completion :
    05/15/2022
    Completion :
    02/05/2025
    TMB
    |
    Keytruda (pembrolizumab)
    Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients (HARMONi-3) (NCT05899608)
    Phase 3
    Summit Therapeutics
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/26/2023
    Primary completion :
    12/31/2027
    Completion :
    12/31/2028
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab)
    Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma (POLESTAR) (NCT05268510)
    Phase 2
    Institut für Klinische Krebsforschung IKF GmbH ...
    Completed
    Last update posted :
    02/20/2025
    Initiation :
    09/15/2022
    Primary completion :
    08/27/2024
    Completion :
    01/09/2025
    HER-2 • PD-L1 • CD8 • CD4
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine • oxaliplatin
    A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) (CheckMate 8KX) (NCT03656718)
    Phase 1/2
    Bristol-Myers Squibb
    Completed
    Last update posted :
    02/20/2025
    Initiation :
    10/29/2018
    Primary completion :
    09/07/2022
    Completion :
    09/12/2024
    MSI
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma (NCT04975152)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/22/2021
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    CD4
    |
    Libtayo (cemiplimab-rwlc)
    Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes (KELLY) (NCT03222856)
    Phase 2
    MedSIR
    Completed
    Last update posted :
    02/19/2025
    Initiation :
    12/14/2017
    Primary completion :
    10/31/2018
    Completion :
    12/23/2020
    HER-2 • PD-L1 • ER • PGR • TMB
    |
    PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Keytruda (pembrolizumab) • Halaven (eribulin mesylate)
    Converting HR+ Breast Cancer Into an Individualized Vaccine (NCT03804944)
    Phase 2
    Weill Medical College of Cornell University
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    03/17/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2027
    HER-2 • PGR
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Mobista (CDX-301)
    A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (NCT05852691)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    07/18/2023
    Primary completion :
    12/24/2026
    Completion :
    12/24/2026
    HER-2 • PD-L1 • ER • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)
    S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (CL1-95029-001) (NCT05162755)
    Phase 1
    Institut de Recherches Internationales Servier
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/15/2021
    Primary completion :
    02/01/2024
    Completion :
    06/19/2025
    HER-2 • KRAS • BRAF • NRAS
    |
    BRAF V600E • KRAS wild-type
    |
    futuximab/modotuximab (S95026) • S95029 • Sym021
    A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors (NCT05836324)
    Phase 1
    Incyte Corporation
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    07/24/2023
    Primary completion :
    12/24/2026
    Completion :
    12/24/2026
    HER-2 • BRAF • ER • PGR • ROS1
    |
    HER-2 negative • ER negative
    |
    INCA33890
    Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer (NCT02907099)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/19/2025
    Initiation :
    12/01/2016
    Primary completion :
    10/06/2023
    Completion :
    10/06/2023
    PD-L1
    |
    Keytruda (pembrolizumab) • Aphexda (motixafortide)
    A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% (RELATIVITY-1093) (NCT06561386)
    Phase 3
    Bristol-Myers Squibb
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/07/2024
    Primary completion :
    07/30/2030
    Completion :
    11/11/2033
    PD-L1
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • pemetrexed • Opdualag (nivolumab/relatlimab-rmbw)
    LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (NCT06216301)
    Phase 3
    NovoCure GmbH
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    07/31/2024
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    PD-L1
    |
    Keytruda (pembrolizumab)
    Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC (JS001-027-III-HCC) (NCT04523493)
    Phase 3
    Shanghai Junshi Bioscience Co., Ltd.
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    06/29/2020
    Primary completion :
    05/31/2025
    Completion :
    09/01/2026
    PD-L1 • TMB
    |
    PD-L1 expression
    |
    Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi)
    Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (M23-385) (NCT05599984)
    Phase 1
    AbbVie
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/05/2022
    Primary completion :
    10/01/2025
    Completion :
    05/01/2027
    EGFR • SEZ6
    |
    EGFR mutation • IDH wild-type
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706